OBJECTIVE-Data regarding long-term outcomes of neonates reaching viability following early preterm premature rupture of membranes (PPROM; <25.0 weeks at rupture) are limited. We hypothesized that babies delivered after early PPROM would have increased rates of major childhood morbidity compared with those with later PPROM (≥25.0 weeks at rupture).
The rate of preterm birth (delivery prior to 37 weeks' gestation) in the United States has recently begun to decline slightly but remains unacceptably high at 11.5% of all deliveries. 1 Preterm premature rupture of membranes (PPROM) is the leading identiable cause of preterm birth and accounts for approximately one third of cases. 2 The etiology of PPROM is multifactorial and is likely related to factors including overt or subclinical infection/ inflammation, abruption, uterine overdistension, smoking, and cervical insufficiency. 3 However, many cases of PPROM occur without a clearly identifiable etiology.
In the United States, women with PPROM prior to 32-34 weeks' gestation are typically given an antibiotic regimen such as erythromycin and ampicillin; antibiotic administration in this setting has been shown to increase the latency period between membrane rupture and delivery and reduce neonatal morbidity and mortality. 4, 5 The majority of women are also administered antenatal corticosteroids to accelerate fetal lung maturity. 6 Given the high risk of secondary complications such as placental abruption, cord prolapse, preterm labor, and intraamniotic infection, women with PPROM are typically managed as in-patients until delivery. In the absence of one of these complications, the majority of women are delivered at or by 32-34 weeks' gestation. The duration of latency between the timing of membrane rupture and delivery appears to be inversely related to the gestational age at PPROM; those women experiencing PPROM earlier in the gestation tend to have the longest latency periods. 7 Traditionally, when PPROM occurs prior to fetal viability (23-25 weeks' gestation), neonatal outcomes have been poor. However, contemporary studies have demonstrated that in an era of advanced neonatal care, outcomes for neonates delivered following very early PPROM may be better than previously expected. 8 Despite advances in neonatal care and apparent improved neonatal outcomes, longer-term outcomes of children delivered following early PPROM are largely unknown. One small study 9 examined early childhood outcomes among 13 neonates who were expectantly managed following spontaneous PPROM at less than 24 weeks; 3 (23%) died in the hospital, and only 2 (15%) survived without obvious long-term morbidity at age 4 years. In another small study, Pristauz et al 10 reported that half of 12 infants surviving PPROM between 14.0 and 24.9 weeks had normal neurological and developmental outcomes at age 2 years.
Therefore, we sought to compare initial neonatal (as assessed at initial hospital discharge) and early childhood outcomes (as assessed at age 2 years) between children with early PPROM (prior to 25.0 weeks' gestation) compared with those with later PPROM (a gestation of 25 weeks 0 days to a gestation of 31 weeks 6 days). We hypothesized that children delivered after early PPROM would have higher rates of neonatal and childhood morbidity and mortality compared with those with later PPROM.
MATERIALS AND METHODS
This is a secondary analysis of a multi-center randomized controlled trial of magnesium sulfate vs placebo for cerebral palsy prevention conducted by the Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network (MFMU) Network. Briefly, women with singleton or twin gestations at high risk for imminent preterm birth were recruited and randomized to receive intravenous magnesium sulfate vs placebo. All women and their infants were followed up to hospital discharge and surviving children were reevaluated at or beyond age 2 years for cerebral palsy and neurodevelopmental outcomes. The methods and results from the primary study have been previously published. 11 Briefly, the main trial found that fetal exposure to magnesium sulfate did not reduce the combined risk of moderate or severe cerebral palsy or death, but the rate of cerebral palsy was reduced among survivors. All participants provided written informed consent at the time of enrollment in the original study. This secondary analysis was performed on a deidentified data set, was reviewed by our local institutional review board, was determined to be nonhuman subject research, and was deemed exempt from institutional review board approval.
For the purposes of this secondary analysis, we included women with singleton gestations who had a confirmed diagnosis of PPROM between 15 and 32 weeks' gestation and subsequently delivered less than 35 weeks' gestation. Women with free-flowing amniotic fluid from the cervix, a positive indigo carmine dye test, and a positive nitrazine and fluid pooling, positive nitrazine and fluid ferning, or positive fluid pooling and fluid ferning were considered to have PPROM.
Neonates diagnosed with major structural congenital anomalies and/or aneuploidy as well as those who delivered at a gestation of 35.0 weeks or longer were excluded from this analysis. With the exception of the study protocol infusion (magnesium sulfate vs placebo), women were managed per local practices with regard to obstetric management, antibiotic administration, and decision to proceed with delivery.
Trained research nurses obtained standardized data on neonatal outcomes during hospitalization and at discharge and at scheduled follow-up visits at 6, 12, and 24 months of age (corrected for prematurity) as a part of the original study. Specifically, each neonate was assessed for the presence of or history of intraventricular hemorrhage, periventricular leukomalacia, bronchopulmonary dysplasia, retinopathy of prematurity, and necrotizing enterocolitis. Additionally, charts were reviewed to determine whether the neonate had 1 or more documented (culture proven) episode(s) of sepsis during their hospitalization. Trained pe-diatricians or pediatric neurologists also evaluated those children who survived to age 2 years. Each child was assessed for the presence of cerebral palsy. Additionally, each child was evaluated with the Bayley II Scales of Infant Development Mental Development (MDI) and Psychomotor Development Indices (PDI).
Those with PPROM less than 25.0 weeks (cases) were compared with women with PPROM at 25.0-31.9 weeks' gestation (controls). Gestational age was determined using the best obstetric estimate, established per standard criteria utilizing menstrual period and ultrasonographic parameters as appropriate. Initially, enrollment in the main trial did not specify a lower gestational age restriction for PPROM. Partway through recruitment, the protocol was amended and only women with PPROM at or beyond 22.0 weeks' gestation were eligible for enrollment.
The primary outcomes of this analysis were as follows: (1) composite severe neonatal morbidity (defined as a diagnosis of sepsis, grade III or IV intraventricular hemorrhage, periventricular leukomalacia, grade II or III necrotizing enterocolitis, bronchopulmonary dysplasia, and/or death) and (2) composite severe childhood morbidity at age 2 years (moderate or severe cerebral palsy, Bayley MDI or PDI scores greater than 2 SD below the mean, and/or death). Outcomes were compared between those with early vs later PPROM.
Demographics, pregnancy characteristics, neonatal course and outcomes, and early childhood outcomes were also compared using a Student t test, χ 2 , and analysis of the variance as appropriate. Multivariable logistic regression was used to assess factors associated with severe neonatal morbidity and severe childhood morbidity; factors significant in the univariable analysis were included in the initial regression models. Covariates were then removed in a stepwise fashion until all covariates in the final model had a value of P < .20. Data were analyzed using STATA version 12.1 (StataCorp, College Station, TX).
RESULTS
Of 2241 women randomized in the original study, 1531 neonates/children met inclusion criteria for this secondary analysis (Figure) . Of these, 275 (18%) were delivered following early PPROM at less than 25.0 weeks' gestation, at a mean gestational age of 23.7 ± 1.2 (range, 15.1-24.9) weeks' gestation. The remaining 1256 (82%) had later PPROM, at a mean gestational age of 28.7 ± 2.2 (range, 25.0-31.9) weeks' gestation.
Maternal demographic and pregnancy characteristics are shown in Table 1 . Women with early PPROM were similar to those with later PPROM with regard to demographics. As expected, the gestational age at the time of randomization was earlier for those with early PPROM, 24.7 vs 28.9 weeks (P < .001). Delivery characteristics and initial neonatal outcomes are shown in Table 2 . Women with early PPROM experienced significantly longer latency-to-delivery intervals yet delivered more than 3 weeks earlier than those with later PPROM.
The vast majority of all women (>98%) received antenatal corticoste-roids, regardless of the timing of membrane rupture. A very small number of women received tocolysis (n = 33, 2.2% overall). The majority (n = 1477, 96.5% overall) received antibiotics between randomization and delivery; 1326 (86.6%) received ampicillin, amoxicillin, or penicillin, and 914 (59.7%) received erythromycin. Unfortunately, the data regarding antibiotic use prior to randomization or the reason/intent for antibiotic prescription are not available.
Neonates delivered following early PPROM were more likely to be delivered by cesarean and in general had higher rates of all adverse outcomes, including death (Table 2 ). Similar trends were seen when examining early childhood outcomes at age 2 years. In univariable analyses, those with early PPROM were more likely to be diagnosed with cerebral palsy and low Bayley II MDI and PDI scores (Table 3) .
When controlling for confounders including gestational age at delivery, PPROM prior to 25 weeks' gestation remained associated with both composite severe neonatal morbidity (odds ratio Table 4 ) and composite severe childhood morbidity (odds ratio, 1.57; 95% confidence interval, 1.12-2.20; Table 5 ). Other factors included in the initial model examining factors associated with adverse neonatal outcomes (Table 4) were the magnesium treatment group, race/ethnicity, and maternal drug use. The initial model examining variables associated with adverse childhood outcomes (Table 5) also included the magnesium treatment group and chorioamnionitis. These factors were excluded from the final models (P > .20).
COMMENT
We found that neonates delivered following early PPROM were at a significantly higher risk for a multitude of adverse outcomes both during the neonatal period and in early childhood. These associations persisted when controlling for confounders, including gestational age at delivery, infectious morbidity, and other factors. Notably, the rates of death during the neonatal period were also significantly higher among those delivered following early PPROM, with nearly 17% of the early PPROM neonates dying, compared with 2.5% of those after later PPROM (P < .001). Rates of death during the initial childhood follow-up period were low and did not differ between groups.
Previous studies of neonatal outcomes among babies reaching fetal viability following early PPROM have reported a wide of both neonatal survival (20-68%) and neonatal morbidity (25-80%). 8, [12] [13] [14] The wide range of outcomes is likely related to an inherent selection bias (given the high rate of elective termination prior to viability), small sample sizes (as few as 25 cases), and the upper gestational age at which PPROM is considered to be early or periviable (which was as high as 28 weeks in some older studies).
Outcome rates in this current study are consistent with these prior reports. Limited data are available regarding outcomes later in life for children who are delivered after early PPROM and survive the initial neonatal period. These data provide valuable insights into the challenges that are faced by children delivered following early PPROM.
The optimal management following early PPROM remains uncertain. In this secondary analysis, women were cared for across the United States at tertiary care centers participating in the MFMU Network; results and outcomes are thus more generalizable to tertiary care centers nationwide. The vast majority received antenatal corticosteroids and antibiotics prior to delivery. Only a very small proportion received tocolysis. This management reflects American College of Obstetricians and Gynecologists' recommendations. 3 Several study limitations must be kept in mind when considering the generalizability of these data. These data cannot provide a population-based estimation of outcomes following PPROM because of the enrollment criteria in the original study and the referral nature of the tertiary care centers participating in the MFMU Network. Also, given that enrollment criteria were changed during the study, those with PPROM less than 22 weeks' gestation were ineligible for the main trial for the majority of the recruitment period. For that reason, the majority of women included in the early PPROM group experienced PPROM between 22 and 25 weeks' gestation. It would be reasonable to conclude that outcomes might be worse if a larger proportion of the population experienced PPROM prior to 22 weeks' gestation, but this cannot be concluded with certainty from these data. Ideally, we would control for delivery gestational age by matching those with early vs later PPROM by delivery gestational age. However, even in this large cohort, we had insufficient numbers to conduct the analysis in this fashion.
Additionally, we were unable to include twin gestations in this secondary analysis because we did not have data regarding which twin's gestational sac was the ruptured sac. Whether these neonatal and early childhood outcome data may be appropriately extrapolated to twin gestations is uncertain.
Lastly, as with any secondary analysis, we were limited by the data collected during the original study. Thus, we do not have data available regarding neonatal outcomes specific to early and prolonged PPROM such as pulmonary hypoplasia and joint contractures. Fortunately, it is likely that babies with pulmonary hypo-plasia would also have bronchopulmonary dysplasia or would not survive; likewise, those with clinically significant joint contractures would have a high change of psychomotor delay at age 2 years; these other diagnoses may be appropriate surrogate outcomes.
Our study had several strengths. This secondary analysis was derived from a large, prospectively collected cohort, providing a relatively large number of women with early PPROM. Data were collected by trained research nurses using standardized definitions and protocols. We were able to compare them with similarly well-characterized women from the same initial study who had PPROM at a later point in pregnancy, reducing potential confounding that could occur if compared with neonatal and childhood outcomes after preterm birth for other indications. Previous studies have suggested that neonatal outcomes are worse following delivery after PPROM vs spontaneous preterm labor. 15 These data provide realistic estimates regarding outcomes after early PPROM from a large cohort of women who sub-sequently achieved sufficient latency to reach fetal viability. Limited data regarding longer-term outcomes of children delivered following early PPROM are currently available. Thus, these data add significantly to the current literature and will be useful in counseling patients regarding pregnancy management and in decisions regarding neonatal resuscitation when PPROM occurs at the limits of viability.
In conclusion, neonates who survive to viability following PPROM during pre-or periviability are at high risk for neonatal death, neonatal morbidity, and significant morbidity in early childhood, even when compared with their later-PPROM counterparts.
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